Evidence map›Paper›PMID 32100140›Full record

ArticleDocumenta ophthalmologica. Advances in ophthalmology2020

Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion: 12-month results.

Tomoharu Nishimura, Shigeki Machida, Atsushi Tada, Eiki Oshida, Tetsuya Muto

Abstract read
PubMed Publisher
In one paragraph

Article in Documenta ophthalmologica. Advances in ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Tomoharu NishimuraDepartment of Ophthalmology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minamikoshiagya, Koshigaya, Saitama, 343-8555, Japan.
Shigeki MachidaDepartment of Ophthalmology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minamikoshiagya, Koshigaya, Saitama, 343-8555, Japan. machidas@dokkyomed.ac.jp.ORCID 0000-0001-8671-2399
Atsushi TadaDepartment of Ophthalmology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minamikoshiagya, Koshigaya, Saitama, 343-8555, Japan.
Eiki OshidaDepartment of Ophthalmology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minamikoshiagya, Koshigaya, Saitama, 343-8555, Japan.
Tetsuya MutoDepartment of Ophthalmology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minamikoshiagya, Koshigaya, Saitama, 343-8555, Japan.
Dokkyo Medical University Saitama Medical Center · JP

Funding

Japan Society for the Promotion of Science 18K09420
6 · The paper itself

Abstract

purposeTo evaluate the 12-month effects of intravitral ranibizumab (IVR) injections on the physiology and morphology of the macula in eyes with a branch retinal vein occlusion with macular edema (BRVOME).

methodsWe studied 13 eyes of 13 patients with a BRVOME. All patients were initially treated with IVR injections at 3 consecutive monthly intervals, the initiation phase. Additional treatments were done according to the pro re nata (PRN) regimen. The physiology of the macula was assessed by the focal macular electroretinograms (fmERGs) and the best-corrected visual acuity (BCVA). The morphology of the macular area was determined by spectral-domain optical coherence tomography. The retina was assessed at the baseline, and at 3, 6, and 12 months after beginning the IVR injections. The fmERGs were elicited by a 15° circular stimulus, and also by 15° semicircular stimuli placed on the occluded or non-occluded side of the macula. The amplitudes of the a- and b-waves, photopic negative response (PhNR), and sums of the oscillatory potentials (ΣOPs) were measured. In addition, the implicit times of the a- and b-waves were measured.

resultsThe BCVA was improved significantly relative to the baseline after the initiation phase (P < 0.01), and it was maintained with the PRN regimen for the 12-month experimental period. The foveal thickness was also significantly decreased after the initiation phase (P < 0.005) but was then worse at 12 months during the maintenance phase (P < 0.05). The fmERGs on the occluded side were significantly reduced at the baseline, and the b-waves and ΣOPs amplitudes improved after the initiation phase. However, they decreased during the PRN period. On the non-occluded side, the amplitudes and implicit times of the a- and b-waves remained unchanged after the initiation phase, the PhNR and ΣOPs amplitudes significantly increased at 3 months compared to the baseline (PhNR, P < 0.005; ΣOPs, P < 0.005), which was maintained throughout the 12 month study period.

conclusionsThe deterioration of the macular function on the occluded side during the maintenance phase suggests that there is a progression of the disease process during the PRN period in eyes with BRVOME.

Indexed as

AgedAged, 80 and overAngiogenesis InhibitorsColor VisionElectroretinographyFemaleFluorescein AngiographyHumansIntravitreal InjectionsMacula LuteaMacular EdemaMaleMiddle AgedRanibizumabRetinal Vein OcclusionTomography, Optical CoherenceAngiogenesis InhibitorsRanibizumabVascular Endothelial Growth Factor AVEGFA protein, humanBRVOFocal macular ERGMacular edemaMacular functionRanibizumab

Identifiers

PMID32100140
OpenAlexW3007280585

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.